AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion

AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence (AI) to target identification and therapeutic design in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies, the companies announced Oct. 15.^1,2 Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in milestones.^1,2

Sharon Barr, executive vice president and head of BioPharmaceuticals research and development at AstraZeneca, tied the agreement to target selection: “We know that disease biology is incredibly complex, and one of the most critical decisions in R&D is selecting the right target. This strategic collaboration underscores our commitment to maximizing the potential of cutting-edge AI to tackle the root cause of disease. Partnering with insitro, we will use advanced AI to identify the biological drivers of disease to support the rapid discovery of high-quality novel targets, advancing our ambition to deliver the next generation of medicines to patients faster.”¹

What are AstraZeneca and insitro agreeing to do?

Insitro will use its Virtual Human platform to identify causal disease biology in both indications and advance AstraZeneca-nominated targets from discovery to development candidate.^1,2 The platform combines large-scale human and cellular data with AI-enabled target identification and medicine design.¹

AstraZeneca will take the clinical development and regulatory work and holds exclusive worldwide rights to the selected programs; insitro’s release adds that AstraZeneca will also lead commercialization.^1,2

Beyond the upfront payment, insitro is eligible for single-digit royalties on global sales.^1,2 The two releases describe the milestones slightly differently: AstraZeneca cites development and commercial milestones, while insitro includes discovery milestones.^1,2

The upfront payment represents less than 3% of the combined headline value, and neither company disclosed the number of targets, program timelines or payment schedule.

Why are MASH and cardiomyopathies difficult to treat?

Insitro’s release says each disease is defined by heterogeneity, with a single diagnostic label covering patients whose underlying biology differs, which has complicated treatment.²

Daphne Koller, Ph.D., founder and CEO of insitro, said: “MASH and cardiomyopathies are prevalent, underdiagnosed diseases where high-content data holds immense potential for uncovering disease drivers. By applying AI to these complex datasets, we can unlock greater discovery power and reveal novel genetic insights. Our platform simultaneously deconvolutes disease biology and identifies causal drivers of disease pathologies. Partnering with AstraZeneca allows us to pair our deep biological precision with their pharmaceutical expertise and scale with potential for accelerated advancement of novel programs through development and to patients.”²

In MASH, the treatment landscape has changed recently. The FDA approved resmetirom (Rezdiffra) in March 2024 under its accelerated approval pathway for adults with noncirrhotic disease and moderate to advanced liver scarring, to be used with diet and exercise. The agency, which at the time referred to the condition as nonalcoholic steatohepatitis, said patients had previously lacked a medication that directly addressed their liver damage, and cited an estimate of 6 million to 8 million U.S. patients at that disease stage.³

The cardiomyopathy picture is less defined in the releases, which do not specify which forms are in scope. Hypertrophic cardiomyopathy, the most common inherited cardiovascular disorder, is estimated to affect 1 in 500 people, and a published review notes that existing studies may have underestimated its prevalence.⁴

That offers one illustration of the underdiagnosis Koller describes, though it should not be read as the collaboration’s target population.

How does the collaboration fit each company’s portfolio?

AstraZeneca describes cardiovascular, renal and metabolism as one of its main disease areas and a key growth driver, with an emphasis on the links among the heart, kidneys, liver and pancreas.¹ A program spanning a liver disease and heart muscle diseases fits within that framing.

Insitro says it has built a multimodal corpus of human and cellular data since 2018 and is advancing nine programs, including genetic regulators of liver fat and fibrosis expected to enter the clinic in early 2027.² The company reports more than $750 million in capital and existing collaborations with Bristol Myers Squibb, Lilly and Gilead.²

The release does not say how its internal liver programs relate to targets AstraZeneca will nominate.

What remains unknown about the collaboration?

No candidate, efficacy data or safety data accompany the announcement, and the collaboration sits at the discovery stage. Targets identified through AI-driven analysis of human data will still need validation through preclinical work and clinical trials, where heterogeneity of disease could also affect trial design.

Milestone and royalty figures are potential payments contingent on progress that neither company has timed publicly. Neither release addresses market reaction, and independent verification of the platform’s performance in these indications was not available at the time of publication.

Sources

1. AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseases. News release. AstraZeneca. October 15, 2026. Accessed October 15, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-announces-new-strategic-collaboration-with-insitro-for-difficult-to-treat-cardiometabolic-diseases.html
2. insitro announces a strategic collaboration with AstraZeneca for AI-enabled discovery of novel therapeutics for MASH and cardiomyopathies. News release. Business Wire. October 15, 2026. Accessed October 15, 2026. https://www.businesswire.com/news/home/20261015984974/en/insitro-Announces-a-Strategic-Collaboration-with-AstraZeneca-for-AI-enabled-Discovery-of-Novel-Therapeutics-for-MASH-and-Cardiomyopathies
3. FDA approves first treatment for patients with liver scarring due to fatty liver disease. News release. US Food and Drug Administration. March 14, 2024. Accessed October 15, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
4. Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol. 2016;13(11):651-675. doi:10.1038/nrcardio.2016.140